Algemeen nieuws

SEP-conclusie: ons onderzoek is van zeer hoog niveau

Oratie Geert-Jan Geersing: de huisarts als grensspecialist

Nieuwe antistoffen ontwikkeld die ontstekingen afremmen bij auto-immuunziekten

Gezicht geven aan de toekomst

“Chirurg in het lab” 

Mensen met diabetes doen liever mee aan klinisch onderzoek vanuit huis

Kinderspierziekte juveniele dermatomyositis beter voorspellen

Nederlands megacohort: samen bouwen aan gezonder ouder worden

UMC Utrecht onderzoekt met 17 miljoen euro samen met het Nederlands Cohorten Consortium hoe mensen gezond ouder worden en ziekten kunnen voorkomen.

Huisartsentekort ontstaat al aan de poort van de universiteit

UMC Utrecht onderzocht de herkomst van 57.958 geneeskundestudenten (2000–2024) en koppelde data om te zien wie arts of huisarts werd.

“We moeten kijken naar de persoon als geheel”

Tuberculosis vaccine does not protect vulnerable elderly people against COVID-19

The BCG vaccine does not offer vulnerable elderly people protection against the symptoms of COVID-19. These are the initial results of the BCG-PRIME study among 6,132 vulnerable patients aged 60 and over. Research into the existing tuberculosis vaccine started in September 2020 and was carried out in 20 Dutch hospitals, including all UMCs and the Santeon top clinical hospitals. The study was headed by Prof. Dr Marc Bonten (UMC Utrecht), Prof. Dr Mihai Netea (Radboudumc), Prof. Dr Frits Rosendaal (LUMC) and Prof. Dr Maurice van den Bosch (OLVG). The Ministry of Health, Welfare and Sport and the Netherlands Organisation of Health Research and Development (ZonMw) funded the study.

International Trial of SARS-CoV-2 Convalescent Plasma Pauses Enrollment of Critically Ill COVID-19 Patients

The REMAP-CAP trial, which is testing the effects of convalescent plasma in COVID-19 patients with moderate and severe illness has paused enrollment for severely ill COVID-19 patients requiring intensive care unit (ICU) support.

Reduced mortality for sickest COVID-19 patients

Treating critically ill COVID-19 patients with drugs typically used for arthritis may significantly improve survival, a landmark study has found. The findings, which have not yet been peer-reviewed, come from the REMAP-CAP trial, which evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU).

Statement from the REMAP-CAP trial: International Trials of Blood Thinners Pause Enrollment of Critically Ill COVID-19 Patients